The role of biologics in treatment of ANCA-associated vasculitis

Dharmapalaiah, Chethana and Watts, Richard A. (2012) The role of biologics in treatment of ANCA-associated vasculitis. Modern Rheumatology, 22 (3). pp. 319-326. ISSN 1439-7595

Full text not available from this repository. (Request a copy)


The vast majority of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) who receive conventional treatment with glucocorticoids and cyclophosphamide experience frequent relapses and treatment-related side-effects. Increasing knowledge of the pathogenesis of AAV has permitted the development of targeted therapies against tumour necrosis factor (TNF)-a and T and B lymphocytes. Therapy with TNF-a blocking drugs has so far proved disappointing, and this approach is not recommended. B cell depletion using rituximab is effective for remission induction, especially in refractory patients. The long-term side-effects and the best method of using rituximab to maintain remission are still to be determined.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Rhiannon Harvey
Date Deposited: 05 Dec 2011 11:34
Last Modified: 22 Oct 2022 21:32
DOI: 10.1007/s10165-011-0548-y

Actions (login required)

View Item View Item